Corbus Pharmaceuticals Holdings (CRBP) Depreciation & Amortization (CF) (2014 - 2025)

Corbus Pharmaceuticals Holdings' Depreciation & Amortization (CF) history runs 12 years deep, the most recent figure standing at $50000.0 for Q3 2025.

• On a quarterly basis, Depreciation & Amortization (CF) fell 67.11% year-over-year to $50000.0 in Q3 2025; TTM through Dec 2025 was $184000.0, a 68.71% decrease from a year earlier, with the FY2024 full-year figure at $588000.0, down 8.27% from the prior year.
• Depreciation & Amortization (CF) eased to $50000.0 in Q3 2025 per CRBP's latest filing, from $53000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $272186.0 in Q1 2021 and bottomed at $50000.0 in Q3 2025.
• The 5-year median for Depreciation & Amortization (CF) is $158130.0 (2023), against an average of $167148.0.
• Across the five-year window, Depreciation & Amortization (CF) gained 26.82% in 2021 and sank 67.11% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $207685.0 in 2021, then declined by 11.21% to $184397.0 in 2022, then fell by 19.74% to $148000.0 in 2023, then slipped by 9.46% to $134000.0 in 2024, then tumbled by 62.69% to $50000.0 in 2025.
• Per Business Quant, the three latest CRBP Depreciation & Amortization (CF) figures stand at $50000.0 (Q3 2025), $53000.0 (Q2 2025), and $81000.0 (Q1 2025).